Yes, it would appear that Dr. Javitt of NeuroRX has taken a page out of the Patterson/Rosenbaum playbook, attempting to take RLFTF's drug and promote it as his own. Apparently, greed is as infectious as covid-19. I disagree with Lang on this one. I believe the drug is effective, not as effective as Leronlimab, but definitely helpful for patients. GEM Global is heavily invested in both RLFTF and NeuroRX, so it's unlikely they will let the dispute get dragged through the courts.